Related Experiment Video

Updated: Feb 9, 2026

Establishing a Porcine Ex Vivo Cornea Model for Studying Drug Treatments against Bacterial Keratitis
09:22

Establishing a Porcine Ex Vivo Cornea Model for Studying Drug Treatments against Bacterial Keratitis

Published on: May 12, 2020

6.2K

Cornea As a Model for Testing CTGF-Based Antiscarring Drugs

Sriniwas Sriram1,2, Jennifer A Tran1,2, James D Zieske1,2

  • 1Schepens Eye Research Institute, Boston, MA, USA.

Bone and Tissue Regeneration Insights
|June 5, 2018
PubMed

Insights

Scarring causes pain and loss of function, driven by Transforming growth factor β1 (TGF-β1) and Connective tissue growth factor (CTGF). The cornea may serve as a novel model for testing anti-CTGF scar therapies.

Area of Science:

  • Wound healing research
  • Fibrosis and scarring mechanisms
  • Ophthalmology and tissue models

Background:

  • Scarring is a significant complication of wound healing, resulting in excessive fibrous tissue, pain, and functional loss.
  • Transforming growth factor β1 (TGF-β1) signaling, particularly its downstream mediator Connective tissue growth factor (CTGF), is central to scar formation.
  • Therapeutic strategies targeting CTGF for scar treatment are gaining research interest.

Purpose of the Study:

  • To propose the cornea as a viable experimental model for evaluating anti-CTGF therapies.
  • To explore the potential of corneal tissue in understanding and mitigating scar-related pathologies.

Main Methods:

  • This article presents a conceptual framework and literature review.
  • It does not involve experimental procedures but rather suggests a research direction.

Main Results:

  • The cornea's unique healing properties and accessibility make it a promising candidate for scar research.
  • Further investigation is warranted to validate its utility in testing anti-CTGF agents.

Conclusions:

  • The cornea offers a unique and potentially advantageous model system for preclinical testing of anti-CTGF therapies aimed at reducing scarring.
  • Utilizing the cornea could accelerate the development of effective scar treatments.
Keywords:
CTGFcorneal scarscarring treatmentsskin scarring

More Related Videos

A Mouse Model of the Cornea Pocket Assay for Angiogenesis Study06:13

A Mouse Model of the Cornea Pocket Assay for Angiogenesis Study

Published on: August 18, 2011

16.4K
Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs12:44

Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs

Published on: January 27, 2023

4.5K

Related Concept Videos

In Vitro Drug Dissolution: Compendial Testing Models I01:13

In Vitro Drug Dissolution: Compendial Testing Models I

Compendial dissolution methods are standardized procedures defined by pharmacopeias to evaluate the rate at which a drug dissolves in a specific medium. These methods ensure batch-to-batch consistency, enable quality control, and support the prediction of drug bioavailability. They are critical for both immediate and modified-release drug products.The apparatuses used for dissolution testing differ in their design and mechanical function, but all aim to simulate the physiological environment of...
296
In Vitro Drug Dissolution: Compendial Testing Models II01:09

In Vitro Drug Dissolution: Compendial Testing Models II

Various dissolution methods are utilized to assess a drug’s dissolution rate, including the flow-through cell, paddle-over-disk, cylinder, and reciprocating disk methods.The flow-through cell apparatus (USP (United States Pharmacopeia) method 4) comprises a reservoir for the dissolution medium and a pump that propels the medium through the cell containing the test sample. This method is crucial for assessing modified-release dosage forms with minimally soluble active ingredients,...
336
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
363
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.3K
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
230
Testes: Histology01:27

Testes: Histology

A tough, fibrous membrane, the tunica albuginea, covers the testes, extending inward to form fibrous partitions or septa, dividing them into internal compartments called lobules. Each lobule has 1 to 3 tightly coiled seminiferous tubules where sperm production occurs. These tubules merge into a tubular network at the back of the testis, known as the rete testis. It connects to 15 to 20 efferent ductules, leading to the epididymis.
The spermatogenic cells, responsible for producing sperm, are...
3.1K